Literature DB >> 7658058

Association of Mycoplasma penetrans with human immunodeficiency virus infection.

O Grau1, B Slizewicz, P Tuppin, V Launay, E Bourgeois, N Sagot, M Moynier, A Lafeuillade, H Bachelez, J P Clauvel.   

Abstract

A cross-sectional study was done to determine the seroprevalence of Mycoplasma penetrans in human immunodeficiency virus (HIV) type 1-seropositive and -seronegative persons recruited in France. The data were analyzed with respect to the sociodemographic, clinical, and biologic status of the patients. M. penetrans seropositivity was associated with HIV infection (18.2% of HIV-seropositive vs. 1.3% of HIV-seronegative persons were M. penetrans-seropositive; P < .001). M. penetrans infection was predominantly but not exclusively associated with homosexual practices in HIV-seropositive subjects and thus presumably sexually transmitted. M. penetrans seroprevalence increased with progression of HIV-associated disease. No association was found between M. penetrans and Kaposi's sarcoma. Thus, there is an unambiguous association between M. penetrans and HIV, particularly among homosexual persons, but its clinical significance remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658058     DOI: 10.1093/infdis/172.3.672

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  The complete genomic sequence of Mycoplasma penetrans, an intracellular bacterial pathogen in humans.

Authors:  Yuko Sasaki; Jun Ishikawa; Atsushi Yamashita; Kenshiro Oshima; Tsuyoshi Kenri; Keiko Furuya; Chie Yoshino; Atsuko Horino; Tadayoshi Shiba; Tsuguo Sasaki; Masahira Hattori
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

2.  Role of Mycoplasma penetrans endonuclease P40 as a potential pathogenic determinant.

Authors:  M Bendjennat; A Blanchard; M Loutfi; L Montagnier; E Bahraoui
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Multiple promoter inversions generate surface antigenic variation in Mycoplasma penetrans.

Authors:  Atsuko Horino; Yuko Sasaki; Tsuguo Sasaki; Tsuyoshi Kenri
Journal:  J Bacteriol       Date:  2003-01       Impact factor: 3.490

4.  Mycoplasma penetrans and other mycoplasmas in urine of human immunodeficiency virus-positive children.

Authors:  A I Hussain; W L Robson; R Kelley; T Reid; J D Gangemi
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

5.  Phase variations of the Mycoplasma penetrans main surface lipoprotein increase antigenic diversity.

Authors:  O Neyrolles; I Chambaud; S Ferris; M C Prevost; T Sasaki; L Montagnier; A Blanchard
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

6.  High prevalence of antibodies to Mycoplasma penetrans in human immunodeficiency virus-seronegative and -seropositive populations in Brazzaville, Congo.

Authors:  P Tuppin; O Delamare; V Launay; M Gueguen; M C Samba; L Pambou; L Montagnier; O Grau
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

7.  In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals.

Authors:  Y Sasaki; A Blanchard; H L Watson; S Garcia; A Dulioust; L Montagnier; M L Gougeon
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 8.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

Review 9.  Mycoplasma blood infection in chronic fatigue and fibromyalgia syndromes.

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2003-07-16       Impact factor: 2.631

10.  Search for the presence of six Mycoplasma species in peripheral blood mononuclear cells of subjects seropositive and seronegative for human immunodeficiency virus.

Authors:  R Kovacic; V Launay; P Tuppin; A Lafeuillade; V Feuillie; L Montagnier; O Grau
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.